Evidence map›Paper›PMID 34385474›Full record

ReviewNature reviews. Disease primers2021

Psoriatic arthritis.

Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, Laura C Coates, Arthur Kavanaugh, William Tillett, Ying Ying Leung, Maarten deWit, Jose U Scher, Philip J Mease

2 registry-linked trialsOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 199 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 10 pooled it
25.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06730334 recruitingnot on this mapstarted 2023, after this paper: background citation

A Single Centre Prospective Cohort Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)

TypeobservationalSponsorNanjing Medical UniversityRan2023 to 2028Enrolled400ConditionsPsoriatic Arthritis, Secukinumab, Ultrasonography
NCT07706530 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 2 Randomized, Double Blind, Clinical Trial (RCT) to Assess the Efficacy, Safety, and Tolerability of Oral CBP-0276 200mg QD, 800mg QD or Placebo for CBP-0276, Administered to Adults With Active Psoriatic Arthritis (PsA).

TypeinterventionalSponsorClarent Biopharma, Inc.Ran2026 to 2027Enrolled240ConditionsArthritic PsoriasisArmsCBP-0276 capsules 100mg, Placebo
3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 10 syntheses or guidelines pooled it, 319 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 5 countries.

Oliver FitzGeraldConway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland. oliver.fitzgerald@ucd.ie.ORCID http://orcid.org/0000-0002-6607-6070
Alexis OgdiePerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Vinod ChandranSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-8297-0275
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Arthur KavanaughCenter for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California, San Diego Medical School, San Diego, CA, USA.ORCID http://orcid.org/0000-0001-6942-5830
William TillettRoyal National Hospital for Rheumatic Diseases, Pharmacy and Pharmacology, University of Bath, Bath, UK.
Ying Ying LeungSingapore General Hospital, Duke-NUS Medical School, Singapore, Singapore.
Maarten deWitGRAPPA Patient Research Partner, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-8428-6354
Jose U ScherDepartment of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1072-6994
Philip J MeaseSwedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6620-0457
New York University · USNuffield Orthopaedic Centre · GBProvidence College · USRoyal National Hospital for Rheumatic Diseases · GBSingapore General Hospital · SGUniversity College Dublin · IEUniversity Health Network · CAUniversity of California San Diego · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying inflammatory musculoskeletal features in joints, entheses or the spine in the presence of skin and/or nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide. The evolution of psoriasis to PsA may occur in stages, although the mechanisms are unclear. In many patients, there may be little or no relationship between severity of musculoskeletal inflammation and severity of skin or nail psoriasis. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved with additional therapies in development. These developments have substantially improved both short-term and long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. With efforts underway aimed at improving our understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible.

Indexed as

Arthritis, PsoriaticPsoriasisHumansSkin

Identifiers

PMID34385474
OpenAlexW4205839940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.